Pradaxa vs. Savaysa

See how Pradaxa and Savaysa compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Pradaxa is taken twice daily while Savaysa is taken once daily, which matters for patients who struggle with multiple daily doses.

  • Both drugs lower stroke risk in nonvalvular atrial fibrillation and treat DVT and PE, but Savaysa is not recommended for people with very high kidney function.

  • Pradaxa has a dedicated FDA-approved reversal agent for emergency bleeding, while Savaysa does not have one specifically approved.

Pradaxa vs. Savaysa Drug Summary

Pradaxa

Pradaxa (dabigatran) is a direct thrombin inhibitor, a type of blood thinner that lowers stroke risk in atrial fibrillation and treats or prevents blood clots like DVT and PE. It's taken as a capsule twice a day, with the dose lowered for severe kidney impairment.

Savaysa

Savaysa (edoxaban) is a factor Xa inhibitor, a type of blood thinner that lowers stroke risk in atrial fibrillation and treats blood clots like DVT and PE. It's taken as a single tablet once a day, at 60 mg or 30 mg depending on weight, kidney function, and other medications.

Pradaxa vs. Savaysa Side Effects

Pradaxa

Most common
GI upset (up to 35%)
GI bleeding (up to 6.6%)
Nausea (up to 5%)
Major bleeding (up to 3.1%)

Savaysa

Most common
Any bleeding (up to 21.7%)
Non-major bleeding (up to 18.1%)
Anemia (up to 9.6%)
Abnormal liver tests (up to 4.8%)

Pradaxa vs. Savaysa Dosage

Pradaxa

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 150 mg twice daily At the start
Maximum dose 220 mg once daily Days 2-35
Dose changes 3 increases Every day

Savaysa

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 60 mg once daily At the start
Maximum dose 30 mg once daily If needed
Dose changes 1 increase As tolerated

Pradaxa vs. Savaysa Indications

Pradaxa

Pradaxa is a direct thrombin inhibitor used to lower stroke risk in people with nonvalvular atrial fibrillation. It also treats deep vein thrombosis and pulmonary embolism, prevents their recurrence, and helps prevent these clots after hip replacement surgery.

  • Reduce stroke risk in nonvalvular atrial fibrillation

  • Treat deep vein thrombosis (DVT) and pulmonary embolism (PE)

  • Prevent recurrent DVT and PE after initial treatment

Savaysa

Savaysa is a factor Xa inhibitor used to lower stroke risk in people with nonvalvular atrial fibrillation, excluding those with very high kidney function. It also treats deep vein thrombosis and pulmonary embolism after a short course of injectable anticoagulant.

  • Reduce risk of stroke and systemic embolism in nonvalvular AF

  • Treatment of deep vein thrombosis (DVT)

  • Treatment of pulmonary embolism (PE)

Pradaxa vs. Savaysa Pros and Cons

Pradaxa

Pradaxa was the first oral direct thrombin inhibitor on the market and has more than a decade of real-world use behind it. It's the only oral anticoagulant with a dedicated reversal agent for emergency bleeding. A generic version helps keep costs down, though the twice-daily schedule and capsule handling rules add extra steps.

Pros

  • Dedicated FDA-approved reversal agent (idarucizumab) for emergency bleeding

  • No boxed warning restricting use in patients with excellent kidney function

  • Approved for more indications, including DVT/PE prevention after hip surgery

Cons

  • Taken twice daily, harder to stay consistent with than once-daily dosing

  • Higher rates of stomach upset and GI irritation (dyspepsia, gastritis-like symptoms)

  • Capsules must be swallowed whole and kept in the original moisture-sensitive bottle

  • Dose must be lowered for severe kidney impairment, adding complexity

Savaysa

Savaysa offers once-daily dosing with a simple two-tier dose selection based on weight, kidney function, and drug interactions. It lacks a dedicated reversal agent and carries a boxed warning against use in atrial fibrillation patients with very high kidney function. As a brand-only medication, it has a narrower list of approved uses than Pradaxa.

Pros

  • Once-daily dosing, simpler to remember than twice-daily Pradaxa

  • No special moisture-sensitive storage requirements for the tablets

  • Simple two-tier dose selection (60 mg or 30 mg) covers most patients

Cons

  • Boxed warning: not recommended for AF patients with excellent kidney function (CrCl >95)

  • No dedicated FDA-approved reversal agent for emergency bleeding

  • Not approved for DVT/PE prevention after orthopedic surgery

  • Brand-only, with no generic version currently available

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.